2. UroToday Home
  3. Conference Highlights
  4. ASCO GU 2018

ASCO GU 2018 Prostate Cancer

ASCO GU 2018: Phase II Trial of 6 Months ADT/Abiraterone Acetate Plus Prednisone and Definitive Radiotherapy - Intermediate to High Risk Localized Prostate Cancer - AbiRT Trial

San Francisco, CA (UroToday.com) Combined external beam radiotherapy (RT) and androgen deprivation therapy (ADT) improves survival over RT alone for high risk prostate cancer (PC). Long-term ADT use, currently recommended for high risk PC, also increases toxicity. Recent data suggests synergistic efficacy with the addition of abiraterone acetate plus prednisone (AAP) to RT/ADT. Potent androgen blockade may provide biochemical control with short-term ADT course in men with aggressive but localized PC.

ASCO GU 2018: Expression of Immune Checkpoints on Circulating Tumor Cells in Men with Metastatic Prostate Cancer 

San Francisco, CA (UroToday.com) Most immune checkpoint inhibitors have shown limited efficacy in unselected men with mPC, and there is limited understanding about which immune checkpoints (ICs) are relevant in mPC. We evaluated ICs on the cell surface of circulating tumor cells (CTCs) in patients with mPC.

ASCO GU 2018: Clinical Utility of Foundation One Tissue Molecular Profiling in Men with Metastatic Prostate Cancer

San Francisco, CA (UroToday.com) In the era of precision medicine, significant effort has been placed on identifying clinically actionable molecular targets to aid in the treatment of metastatic prostate cancer (mPC). Recent data supports homologous repair and mismatch repair deficiencies to guide the use of PARP inhibitors/platinum chemotherapy or pembrolizumab, respectively. We analyzed the clinical utility of Foundation One (FO) somatic genomic profiling in men with mPC.

ASCO GU 2018: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic Castrate Resistant Prostate Cancer

San Francisco, CA (UroToday.com) Bone scans were not obtained in the phase 3 ALSYMPCA trial, and retrospective series have reported varying rates of development of new lesions and resolution of existing lesions, following treatment with Radium-223 (Ra-223).

ASCO GU 2018: Retrospective Analysis of Fatigue in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide

San Francisco, CA (UroToday.com) Enzalutamide, an androgen axis inhibitor, has had an increasingly important role in the management of advanced prostate cancer. Currently approved for metastatic castration-resistant prostate cancer (mCRPC), there is growing evidence it may have a role in earlier stages of prostate cancer progression.

ASCO GU 2018: Abiraterone or Docetaxel in Men with Metastatic Castration-sensitive Prostate Cancer: A Pooled Analysis of Castration Resistance-free Survival and Toxicity

San Francisco, CA (UroToday.com) The management of metastatic prostate cancer (PCa) continues to change in rapid succession. While we were once reliant on androgen-deprivation therapy for hormone-sensitive prostate cancer (hsPCa) and docetaxel alone for the treatment of metastatic castration-resistant PCa (mCRPC), the landscape of PCa treatment has drastically changed.

ASCO GU 2018: Real-world Study of Enzalutamide and Abiraterone Acetate (with Prednisone) Tolerability (REAAcT): Results

San Francisco, CA (UroToday.com) Oral enzalutamide and abiraterone (coadministered with prednisone), both androgen axis inhibitors introduced in the past decade, have had an immediate impact on the management of advanced prostate cancer. Approved for men with metastatic castration-resistant prostate cancer, demonstrating significant PFS, CCS and OS benefit, they have become commonly used in this setting.
Page 1 of 13